NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- State
- Under way
- Phase
- Phase 2
- People
- 6,452 planned
- Started
- 17 Aug 2015
- Primary completion
- 31 Dec 2027
- Arms
- Subprotocol I (PIK3CA mutation)
- Results
- None posted
- 8 Jun 2015: Trial registered
- 17 Aug 2015: Trial started